Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Actuate Therapeutics IncNASDAQ: ACTU

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$160.23M, compared with -$138.7M a year earlier.

Context

  • Retained earnings amounted to 1798.1% of total assets at the end of Q1 FY2026, down 1295.7 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -15.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$160.23M-3.6% QoQ
Last fiscal yearDec 2025
-$154.61M-16.8% YoY
Year agoMar 2025
-$138.7M-15.5% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.5%——
1 year-16.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(154.61M) USD
Year-over-year change
-16.8%

Retained Earnings vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -15.5% is the 4th highest of 9, against a peer median of -18.5%.
  • Retained earnings amounts to 1798.1% of total assets for ACTU, versus a peer median of 392.5%.
ACTU Competitors
Retained Earnings for ACTU and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACTUActuate Therapeutics IncMar 2026-$160.23M USD-15.5%—1798.1%
ELTXElicio Therapeutics, Inc.Mar 2026-$245.5M USD-19.6%—1082.0%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
PEPGPepGen Inc.Mar 2026-$378.88M USD-25.6%—242.4%
SPROSpero Therapeutics, Inc.Mar 2026-$458.27M USD+3.2%—776.5%
NKTXNkarta, Inc.Mar 2026-$676.14M USD-17.3%—181.7%
MCRBSeres Therapeutics, Inc.Mar 2026-$992.32M USD-5.0%—843.7%
ALECAlector, Inc.Mar 2026-$994.99M USD-14.4%—414.7%
VORVor Biopharma Inc.Mar 2026-$1.37B USD-180.4%—270.9%
Peer median (excluding ACTU) —-18.5%—392.5%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.45M2.96M8.64M13.16M
Short-term Investments0000
Net Receivables0000
Inventory0000
Other Current Assets33.75K36.91K0484K
Total Current Assets20.48M3M9.21M13.64M
Property, Plant & Equipment (Net)0000
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets00110.55K392.49K
Total Non-current Assets00110.55K392.49K
Total Assets20.48M3M9.32M14.04M
Account Payables2.13M3.42M1.92M1.52M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities2.08M277.5K03.59M
Total Current Liabilities4.34M6.92M8.8M5.71M
Long-term Debt404.99K00404.99K
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities900.76K95.7M411.76K0
Total Non-current Liabilities1.31M95.7M411.76K404.99K
Total Liabilities5.65M102.62M9.21M6.11M
Common Stock322023
Retained Earnings(80.35M)(105.09M)(132.38M)(154.61M)
Accumulated OCI0(0)00
Other Stockholders Equity01(834)0
Minority Interest0000
Total Equity14.83M(99.63M)104.19K7.92M
Total Debt404.99K00404.99K
Net Debt(20.04M)(2.96M)(8.64M)(12.75M)

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.